Details for New Drug Application (NDA): 205229
✉ Email this page to a colleague
NDA 205229 describes PROGESTERONE, which is a drug marketed by Amneal Pharms Ny, Bionpharma, Dr Reddys, Eugia Pharma, Sofgen Pharms, Teva Pharms, Xiromed, Accord Hlthcare, Actavis Labs Ut Inc, Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, and Lilly, and is included in fifteen NDAs. It is available from twenty-one suppliers. Additional details are available on the PROGESTERONE profile page.
The generic ingredient in PROGESTERONE is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the progesterone profile page.
The generic ingredient in PROGESTERONE is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the progesterone profile page.
Summary for 205229
| Tradename: | PROGESTERONE |
| Applicant: | Xiromed |
| Ingredient: | progesterone |
| Patents: | 0 |
Suppliers and Packaging for NDA: 205229
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PROGESTERONE | progesterone | CAPSULE;ORAL | 205229 | ANDA | Northstar Rx LLC | 16714-157 | 16714-157-01 | 100 CAPSULE in 1 BOTTLE (16714-157-01) |
| PROGESTERONE | progesterone | CAPSULE;ORAL | 205229 | ANDA | Northstar Rx LLC | 16714-158 | 16714-158-01 | 100 CAPSULE in 1 BOTTLE (16714-158-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Oct 20, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 200MG | ||||
| Approval Date: | Oct 20, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
